Voyager Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning, and welcome to the 42nd Annual JPMorgan Healthcare Conference. My name is Dave Praharaj, and I'm part of the Healthcare Investment Banking team here at JPMorgan.
Today, I have the pleasure of introducing our speaker, Dr. Al Sandrock, CEO of Voyager Therapeutics. In terms of logistics, please reserve any questions for after the presentation as we will have time. With that, take it away, Al.
Thank you very much. Thank you very much. Good morning, ladies and gentlemen, and it's my pleasure to tell you about Voyager and how we're defining neurogenetic medicines. What I'll be telling you about today is basically 4 things: our pipeline, which consists of a wholly owned pipeline as well as some partner programs in neurogenetic medicines with at least 4 IND filings this year and next year, potentially generating clinical data in 2025 and 2026.
I'll be telling you about our platform, focus on our TRACER-derived capsids. We believe this is a leading
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
